

For Immediate Release

Net Revenues up 19%, Net Profit up 8%

Vadodara, 31st July, 2015

Alembic Pharmaceuticals Limited reported its performance for the first quarter ending 30th June 2015. The consolidated results were taken on record by the board of directors at a meeting held in Vadodara today.

Financial Highlights

- Net Sales up 19% to Rs 590 Crore
- Net Profit up 8% to Rs 70 crore
- India Branded Formulation up 18% to Rs. 263 crore
- International Generics up 47% for the quarter to Rs. 168 Crore

Commenting on the results, Mr. Shaunak Amin, Joint Managing Director, Alembic Pharmaceuticals Limited said "We have seen exceptional growth in the topline on all the businesses, we however have also accelerated our R&D program, which led to an expense increase of 62% which has impacted our margins"

Operational Highlights

India Branded Formulations Business

- The India Branded formulations business grew by 18% to Rs 263 crores in the quarter against Rs 223 crores
- Specialty Segment grew by 22% and Acute Segment grew by 12%
- Alembic's "Tellzy" is the fastest growing Telmisartan brand, 50% as per ORG MAT May 2015, and is now the 3rd ranked brand in the Telmisartan market.

CIN:
Page: 1 of 3
L24230GJ2010PLC061123

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2282506
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

International Generics

- Successful Launch of Aripiprazole Generic on Day 1
- International Generics grew by 47% to Rs 168 crores in the quarter.
- During the quarter 8 ANDA approvals were received.
- 1 DMF application was filed during the quarter, taking cumulative DMF filings of the Company to 73.
- Successfully audited by the USFDA at API Karkhadi Plant

Summary of Total Revenue is as under:

(Rs in Lacs)			
Particulars	Q1 FY16	Q1 FY15	% Change
Formulation			
India Branded	26275	22328	18%
India Generics	2859	2522	13%
International Branded	836	2268	(-)63%
International Generics	16768	11381	47%
API	11683	10631	10%
Export Incentives	611	483	
Total	59032	49613	19%

The Profit break-up is as under:

(Rs in Lacs)			
Particulars	Q1 FY16	Q1 FY15	% Change
EBITDA	10205	9602	6%
Profit Before Tax	8857	8493	4%
Net Profit after Tax	6988	6467	8%

Page: 2 of 3
L24230GJ2010PLC061123

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2282506
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 – 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 – 3007630 Email: mitanshu.shah@alembic.co.in
---	---